Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) CEO Sells 27,098 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum sold 27,098 shares of Hims & Hers Health stock in a transaction dated Thursday, January 23rd. The shares were sold at an average price of $30.08, for a total transaction of $815,107.84. Following the sale, the chief executive officer now owns 27,918 shares in the company, valued at approximately $839,773.44. This represents a 49.25 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Andrew Dudum also recently made the following trade(s):

• On Tuesday, January 21st, Andrew Dudum sold 300 shares of Hims & Hers Health stock. The shares were sold at an average price of $30.00, for a total transaction of $9,000.00.
• On Thursday, January 16th, Andrew Dudum sold 36,460 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.09, for a total transaction of $987,701.40.
• On Monday, December 16th, Andrew Dudum sold 78,127 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.62, for a total transaction of $2,314,121.74.
• On Monday, December 2nd, Andrew Dudum sold 33,513 shares of Hims & Hers Health stock. The shares were sold at an average price of $33.38, for a total value of $1,118,663.94.
• On Tuesday, November 5th, Andrew Dudum sold 188,888 shares of Hims & Hers Health stock. The stock was sold at an average price of $20.88, for a total value of $3,943,981.44.

Hims & Hers Health Trading Down 0.0 %

NYSE:HIMS traded down $0.00 on Friday, hitting $30.89. 8,946,218 shares of the company’s stock traded hands, compared to its average volume of 10,210,918. The company has a market cap of $6.75 billion, a PE ratio of 70.20 and a beta of 1.31. Hims & Hers Health, Inc. has a 1 year low of $8.51 and a 1 year high of $35.02. The firm has a 50-day moving average price of $27.98 and a 200-day moving average price of $22.09.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm had revenue of $401.56 million for the quarter, compared to the consensus estimate of $382.20 million. During the same period in the previous year, the firm posted ($0.04) earnings per share. The firm’s revenue was up 77.1% on a year-over-year basis. On average, research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hedge Funds Weigh In On Hims & Hers Health

A number of hedge funds have recently modified their holdings of HIMS. Wellington Management Group LLP grew its stake in Hims & Hers Health by 34.5% in the third quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock valued at $63,446,000 after purchasing an additional 883,230 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Hims & Hers Health by 12.7% during the 3rd quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company’s stock valued at $79,029,000 after buying an additional 482,177 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund grew its stake in shares of Hims & Hers Health by 164.1% in the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 528,142 shares of the company’s stock valued at $10,663,000 after buying an additional 328,142 shares in the last quarter. Carnegie Investment Counsel bought a new position in Hims & Hers Health during the third quarter valued at approximately $5,531,000. Finally, Blueshift Asset Management LLC grew its position in Hims & Hers Health by 834.8% in the third quarter. Blueshift Asset Management LLC now owns 245,013 shares of the company’s stock worth $4,513,000 after acquiring an additional 218,804 shares in the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have commented on HIMS shares. Morgan Stanley assumed coverage on shares of Hims & Hers Health in a research report on Tuesday, December 17th. They issued an “overweight” rating and a $42.00 price target on the stock. Canaccord Genuity Group increased their target price on shares of Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a research note on Monday, December 2nd. BTIG Research initiated coverage on shares of Hims & Hers Health in a research report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price target on the stock. Needham & Company LLC increased their price objective on Hims & Hers Health from $28.00 to $31.00 and gave the company a “buy” rating in a research report on Monday, January 6th. Finally, Bank of America cut Hims & Hers Health from a “buy” rating to an “underperform” rating and decreased their target price for the stock from $32.00 to $18.00 in a report on Thursday, November 14th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $25.13.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.